Immunotherapy for B-Cell Neoplasms Using T-Cells Expressing Chimeric Antigen Receptors : From Antigen Choice to Clinical Implementation

Boulassel, Mohamed Rachid; Galal, Ahmed

doi:10.12816/0003140

Cited by 2 publications

(3 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, clinical trials utilizing the second generation CD19 CAR-T cells to treat hematological malignancies have resulted in the most encouraging clinical responses 21 , and the CD19-CAR T cell therapy (CTL019) has been highly appraised and approved as the breakthrough therapy by the FDA. Currently, adoptive CAR-T cells focusing on CD20 are also being evaluated in clinical trials for the treatment of B-cell malignancies, for which other CAR-T cells targeting CD22, CD30 and CD33 are now at the stage of in vitro trials 22 . At present, CAR-T cell therapy has demonstrated success as a novel treatment modality that the commercial manufacture of gene-modified T cells at industrial scale for the treatment of advanced cancers is becoming a hotspot worldwide.…”

Section: Development and Clinical Application Of Carsmentioning

confidence: 99%

New Strategies for the Treatment of Solid Tumors with CAR-T Cells

Zhang¹,

Ye²,

Yuan³

et al. 2016

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Recent years, we have witnessed significant progresses in both basic and clinical studies regarding novel therapeutic strategies with genetically engineered T cells. Modification with chimeric antigen receptors (CARs) endows T cells with tumor specific cytotoxicity and thus induce anti-tumor immunity against malignancies. However, targeting solid tumors is more challenging than targeting B-cell malignancies with CAR-T cells because of the histopathological structure features, specific antigens shortage and strong immunosuppressive environment of solid tumors. Meanwhile, the on-target/off-tumor toxicity caused by relative expression of target on normal tissues is another issue that should be reckoned. Optimization of the design of CAR vectors, exploration of new targets, addition of safe switches and combination with other treatments bring new vitality to the CAR-T cell based immunotherapy against solid tumors. In this review, we focus on the major obstacles limiting the application of CAR-T cell therapy toward solid tumors and summarize the measures to refine this new cancer therapeutic modality.

show abstract

Section: Development and Clinical Application Of Carsmentioning

confidence: 99%

New Strategies for the Treatment of Solid Tumors with CAR-T Cells

Zhang¹,

Ye²,

Yuan³

et al. 2016

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…No entanto, a transfecção com fosfato de cálcio é altamente sensível a variações no pH, resultando em baixa reprodutibilidade (KURODA et al, 2009). Outros métodos menos laboriosos existem, como o uso do polímero Polietilenoimina (PEI) (BOUSSIF et al, 1995;DONG et al, 2007;LONGO et al, 2013) e os lipídeos catiônicos (FELGNER et al, 1987;MA et al, 2007). O PEI é um polímero catiônico que forma um complexo com o DNA, e neutraliza as cargas negativas presentes nos ácidos nucleicos (BOUSSIF et al, 1995).…”

Section: Receptor Quimérico De Antígenosunclassified

“…Outros métodos menos laboriosos existem, como o uso do polímero Polietilenoimina (PEI) (BOUSSIF et al, 1995;DONG et al, 2007;LONGO et al, 2013) e os lipídeos catiônicos (FELGNER et al, 1987;MA et al, 2007). O PEI é um polímero catiônico que forma um complexo com o DNA, e neutraliza as cargas negativas presentes nos ácidos nucleicos (BOUSSIF et al, 1995). Esse complexo sofre então endocitose e o DNA é liberado dentro do citoplasma celular.…”

Section: Receptor Quimérico De Antígenosunclassified

Estabelecimento de uma plataforma para produção de vetores lentivirais para a modificação de linfócitos T com CAR anti-CD19

Moço¹

View full text Add to dashboard Cite

Aos meus pais, Antônio e Maura, e irmã, Bianca, por sempre acreditarem em mim e me apoiarem em todas as minhas decisões, nem que isso significasse ficar meses sem poder visitá-los. À minha amada Bárbara, por todo o companheirismo, amor e incentivo recebidos dia após dia. À professora Virgínia Picanço e Castro, pela orientação no desenvolvimento deste trabalho. A todos do grupo de CART cells, Amanda Mizukami, Letícia Delfini, Marcelo Pereira, Renata Silvestre, e professoras Kamilla Swiech e Kelen Farias, por todas as contribuições a esse trabalho.

show abstract

Immunotherapy for B-Cell Neoplasms Using T-Cells Expressing Chimeric Antigen Receptors : From Antigen Choice to Clinical Implementation

Cited by 2 publications

References 64 publications

New Strategies for the Treatment of Solid Tumors with CAR-T Cells

New Strategies for the Treatment of Solid Tumors with CAR-T Cells

Estabelecimento de uma plataforma para produção de vetores lentivirais para a modificação de linfócitos T com CAR anti-CD19

Contact Info

Product

Resources

About